|Articles|July 28, 2022

Boehringer Ingelheim to Use Seqster Platform

Patients in all studies can consent to longitudinal data use to accelerate RWE

Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.

Read more about the partnership.

Listen to a podcast with Seqster CEO & Co-founder Ardy Arianpour.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content